Protocol Ledger

NCT05799287 · Phase III · ACTIVE NOT RECRUITING

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Interventional Phase III clinical trial protocol NCT05799287 sponsored by RemeGen Co in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-28 Enrollment: 318 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05799287
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)318 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05799287
Protocol FieldVerified Registry Value
NCT IdentifierNCT05799287
Consolidated Lead SponsorRemeGen Co
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment318 participants (ACTUAL)
Registered Start Date2023-04-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI